Tag: biotechnology
-
Grant Funding Study of Gut Microbe Protection Drug
A biotechnology company developing drugs that protect the natural microbial balance in the gastrointestinal tract is receiving funds to learn how its drugs affect antibiotic resistance.
-
Gene Silencing Treatments Licensed for Heart Disease
Biopharmaceutical company Amgen is acquiring the rights to a technology that stops the actions of inherited genes associated with a leading type of heart disease.
-
Material Developed for 3-D Printed Bone
A synthetic material called hyperelastic bone is shown to produce replacement bone with a 3-D printer and in lab animals supports the growth of new bone without causing an immune response.
-
Harvard Spin-Off to Sequence, Visualize RNA in Tissue
A new spin-off enterprise from Harvard University is commercializing technology that enables sequencing and imaging of genetic transcriptions of cells in their original tissue.
-
Trial Shows Engineered T-Cells Can Stop Lymphoma
Early results of a clinical trial show an individual’s own immune system cells altered to attack non-Hodgkin lymphoma can cause a partial or complete response in a large percentage of patients.
-
DoD Grant Funds Exosome Manufacturing Process
A biotechnology company is receiving a Department of Defense grant to develop a commercial-scale manufacturing process for exosomes, tiny bubbles that deliver drugs to cells in the body.
-
Spin-Off Companies to Develop Chronic Disease Therapies
Two new spin-off enterprises are being created to develop gut-based treatments for chronic diseases using technologies from synthetic biology company Intrexon Corporation.
-
Monsanto Licensing MIT/Harvard Genome Editing
Monsanto Company is licensing genomic editing technology for agricultural applications from a joint research center at Harvard University and MIT.
-
Antibiotic Shown to Control Drug-Resistant Gonorrhea
Findings from a clinical trial show a candidate drug kills bacteria causing a type of gonorrhea becoming resistant to current antibiotics.
-
Genentech, BioNTech Partner on Personal Cancer Therapies
Biotechnology company BioNTech AG is licensing its messenger RNA technology and collaborating with biopharmaceutical company Genentech to develop personalized cancer immunotherapies.